IMMX Stock Analysis: Buy, Sell, or Hold?
IMMX - Immix Biopharma, Inc. Common Stock
$9.94
-0.16 (-1.58%)
▼
5d:
+1.95%
30d:
-0.2%
90d:
+35.61%
BUY
HIGH Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 14, 2026
0d
Smart Money Distribution
IMMX is up 5.9% this week, but smart money is buying puts. Top strike: $10 2026-06-18 with 3,050 OI. Put ratio: 100% View Scanner →
Strength: 7.9/10
Get Alerted When IMMX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
4 traders called IMMX this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: IMMX shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: IMMX shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: IMMX is currently trading at $9.94, which is considered fair relative to its 30-day fair value range of $9.26 to $10.26.
Technical Outlook: Technically, IMMX is in a strong uptrend. Immediate support is located at $8.82, while resistance sits at $10.77.
Market Sentiment: IMMX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $17.56 (+76.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IMMX is in a strong uptrend. Immediate support is located at $8.82, while resistance sits at $10.77.
Market Sentiment: IMMX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $17.56 (+76.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$9.26 -
$10.26
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
89.6%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 76.7% below Wall St target ($17.56)
Trading Range Analysis
30-Day Trading Range
$9.26 -
$10.26
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$1.06
(10.7%)
Support & Resistance Levels
Support Level
$8.82
Resistance Level
$10.77
Current Trend
Strong Uptrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-14.00
Wall Street Target
$17.56
(+76.7%)
Share & Embed Analysis
Last updated: May 18, 2026 6:07 AM ET
Data refreshes hourly during market hours. Next update: 7:07 AM
Data refreshes hourly during market hours. Next update: 7:07 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IMMX showing a specific setup today?
Insider Activity (6 Months)
2
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Gabriel S Morris
BUY
770 shares
2025-12-10
Ilya M Rachman
BUY
746 shares
2025-12-10
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 55 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 56 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 63 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 55 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$203 | 52 HOLD |
